FDA Approves a Weekly Insulin for Adults With Type 2 Diabetes
The FDA approved Lilly’s Onswik as a once-weekly basal insulin for adults with type 2 diabetes. Four Phase 3 trials found blood-sugar control that was not inferior to daily basal insulin, but the drug is not approved for type 1 diabetes and still carries hypoglycaemia risks.
The US Food and Drug Administration has approved Onswik, Eli Lilly's insulin efsitora alfa, as a once-weekly basal insulin for adults with type 2 diabetes. The decision turns a treatment normally taken every day into one injection every seven days, although US availability is expected only in the coming months.
Quick summary
- Onswik is a long-acting insulin for adults with type 2 diabetes who need basal insulin.
- It is injected once weekly and was tested against daily basal insulins in four Phase 3 trials involving more than 3,400 adults.
- The trials showed that weekly efsitora was not inferior to daily comparators for lowering glycated haemoglobin, or HbA1c.
- It is not approved for type 1 diabetes, children or adolescents.
Basal insulin supplies a steady background level of insulin between meals and overnight. Lilly developed efsitora to remain active for a full week, reducing the number of routine injections from about 365 to 52 a year for someone who would otherwise inject once daily.
Key number: a weekly schedule can remove 313 basal-insulin injections from a year of treatment compared with one injection every day.
The approval rests on the QWINT clinical programme. Its four late-stage studies enrolled adults at different points in type 2 diabetes care, including people who had never used insulin and people already taking basal insulin. The programme compared efsitora with daily insulin glargine or insulin degludec.
In QWINT-1, published in the New England Journal of Medicine, 795 adults who had not previously used insulin received weekly efsitora or daily glargine. The primary result was non-inferiority in HbA1c reduction. That means the trial was designed to show that the weekly treatment did not lose more glucose-lowering effect than a prespecified margin, not that it was clinically superior in every respect.
Convenience could matter because injection burden is one reason some people delay or struggle with insulin therapy. A weekly option may simplify routines, but approval does not prove that every patient will adhere better. Dosing errors may also be harder to correct quickly when a medicine is intended to act for seven days.
Reality check
Onswik remains insulin, so low blood sugar is still a central safety concern. The FDA did not approve it for type 1 diabetes after trials in that population showed a higher rate of severe hypoglycaemia. The label also requires careful switching from other insulin regimens, and patients still need individual monitoring and dose adjustment. The Phase 3 evidence establishes comparable average glucose control, not better long-term protection from complications or proven improvements in adherence.
Onswik will be supplied in prefilled pens at concentrated strengths. Clinicians will decide whether the weekly format fits a patient's current medicines, glucose patterns and ability to follow a seven-day schedule. The approval adds another weekly basal-insulin choice in the United States; Novo Nordisk's Awiqli received US approval earlier in 2026, so Onswik is not the country's first.
Verified topics and entities
Sources and citations4 sources
External references used to support the reporting in this article.
- Reuters: US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes
- Eli Lilly: FDA approves Onswik once-weekly insulin
- New England Journal of Medicine: Once-Weekly Insulin Efsitora Alfa in Type 2 Diabetes without Previous Insulin Treatment
- PubMed: QWINT Phase 3 programme design for once-weekly insulin efsitora alfa
Published by
NewTqnia Health Desk
An institutional editorial team within NewTqnia
